Keywords
How to Cite
Abstract
Objective: To determine the mean change in intraocular pressure at 05, 30 min, 1 and 2 weeks after intravitreal injection of anti-vascular endothelial growth factor.
Study Design: Quasi-Experimental
Duration: 7th February 2024 to 6th September 2024
Material & Methods: This study includes a total of 100 patients, both male and female, aged >35 and <70 years. The patients included had undergone a comprehensive ophthalmic examination, which included a history, intraocular pressure using a Goldman applanation tonometer, subjective and objective refraction by autorefractometer, pinhole test, slit lamp examination of the adnexa, anterior segment examination, and fundus examination with 90D and 78D. In suspected DME, ARMD, CRVO, and BRVO patients who presented with decreased near vision and metamorphasia, we measured the thickness of the macular and retinal nerve fiber layer using OCT SD on a Heidelberg machine to validate the requirement for anti-vgef.
Results: One hundred participants, with an average age of 56.76 ± 12.88, were enrolled in this study. The study population, which consisted of 62 people (62%), was primarily male. Sixty-four percent of the patients, or 64 people, were older than 55. In 18% of instances, age-related macular degeneration (ARMD) was found. Intraocular pressure measurements (in mmHg) were measured at baseline, five minutes, thirty minutes, after the first week, and after the second week using repeated measures ANOVA. Statistical significance was found in the study's findings (p<0.001*). In particular, the mean intraocular pressure rose from baseline to 5 and 30 minutes; nevertheless, it was noted that the intraocular pressure values considerably decreased to baseline levels at the first and second weeks.
Conclusion: Anti-VEGF medication IVIs are safe, although they may cause elevated intraocular pressure. IOP frequently rises quickly and temporarily after IVI, although most patients see a sharp decline within 30 minutes of the injection.